title: Alteration of RhoA Prenylation Ameliorates Cardiac and Vascular Remodeling in Spontaneously Hypertensive Rats.
abstract: BACKGROUND
  In our previous study, farnesyl pyrophosphate synthase (FPPS) was shown to be increased in spontaneously hypertensive rats (SHR) and in mice with angiotensin-II induced cardiac hypertrophy. Overexpression of FPPS induced cardiac hypertrophy and fibrosis in mice, accompanied by an increase in the synthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). In the present study, we investigated the mechanisms of reversing cardiovascular remodeling in SHR by inhibiting FPPS.
  
  
  RESULTS
  Six-week-old rats were given vehicle or an FPPS inhibitor (alendronate, 100 ug/kg/d) daily for twelve weeks by osmotic mini-pump. The results demonstrated that FPPS inhibition attenuated cardiac hypertrophy and fibrosis in SHR as shown by the heart weight to body weight ratio, echocardiographic parameters, and histological examination. In addition, FPPS inhibition attenuated aortic remodeling as shown by reduced media thickness, media cross-sectional area and collagen of the aorta as well as SBP, DBP, MBP. Furthermore, 12 weeks of alendronate treatment significantly decreased FPP and GGPP levels, RhoA activation and geranylgeranylation in the heart and aorta, all of which were significantly upregulated in SHR compared with normotensive Wistar-Kyoto rats.
  
  
  CONCLUSIONS
  Taken together, these results indicate that chronic treatment with alendronate decreases the development of cardiac and aortic remodeling, by a pathway which involves inhibition of the geranylgeranylation and activation of RhoA.
authors.affiliation: Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Yang
authors.forename: Yu-Ning
authors.initials: YN
authors.lastname: Chen
authors.forename: Zao-Xian
authors.initials: ZX
authors.lastname: Xu
authors.forename: Yun
authors.initials: Y
authors.lastname: Mou
authors.forename: Liang-Rong
authors.initials: LR
authors.lastname: Zheng
mesh_terms: D019386:Alendronate / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology; D006332:Cardiomegaly / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D003094:Collagen / Q000378:metabolism; D004452:Echocardiography / Q000379:methods; D005355:Fibrosis / Q000517:prevention & control; D051228:Geranyltranstransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D011106:Polyisoprenyl Phosphates / Q000378:metabolism; D054876:Prenylation / Q000187:drug effects; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D012717:Sesquiterpenes / Q000378:metabolism; D013045:Species Specificity; D066253:Vascular Remodeling / Q000187:drug effects / Q000502:physiology*; D020257:Ventricular Remodeling / Q000187:drug effects / Q000502:physiology*; D020742:rhoA GTP-Binding Protein / Q000378:metabolism*
chemical_list: D050071:Bone Density Conservation Agents; D011106:Polyisoprenyl Phosphates; D012717:Sesquiterpenes; C004808:farnesyl pyrophosphate; D003094:Collagen; D051228:Geranyltranstransferase; D020742:rhoA GTP-Binding Protein; C002963:geranylgeranyl pyrophosphate; D019386:Alendronate